Complex Structure and Regulation of the P16 (MTS1) Locus

Cancer Research

Volumn 55, Issue 14, 1995, Pages 2988-2994

  Stone, Steven ^a   Jiang, Ping ^a   Dayananth, Priya ^a   Tavtigian, Sean V ^a   Katcher, Harold ^a   Parry, David ^b   Peters, Gordon ^b   Kamb, Alexander ^a  

^a Myriad Genetic Laboratories   (United States)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CARRIER PROTEINS; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMAN; LYMPHOCYTES; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTEIN P16; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0029060657     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Shcrr, C. J. Mammalian Gl cyclins. Cell, 73: 1059–1065, 1993.
2. Shcrr, C. J. Gl phase progression: cycling on cue. Cell, 79: 551–555, 1994.
3. Peter, M., and Herskowitz., I. Joining the complex: cyclin-dcpendcnt kinase inhibitory proteins and the cell cycle. Cell, 79: 181–184, 1994.
4. El-Deiry, W. R., Tokino, T., Vclculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M.,Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817–825, 1993.
5. Gu, W., Turck, C. W., and Morgan, D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond.), 366: 707–710, 1993.
6. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, K. K. The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell, 75: 805–816, 1993.
7. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704–7, 1993.
8. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701–704, 1993.
9. INK4B is a potential effector of TFG-β-induced cell cycle arrest. Nature (Lond.), 371: 257–260, 1994.
10. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59–66, 1994.
11. Toyoshima, H., and Hunter, T. p27, a novel inhibitor of Gl cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67–74, 1994.
12. NK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939–2952, 1994.
13. INK4/MTS1 tumour suppressor gene product. EMBO J., 14: 503–511, 1995.
14. INK4. Science (Washington DC), 267: 249–252, 1995.
15. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor pl6 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078–6082, 1994.
16. Ink4. Cancer Res., 54: 5816–5820, 1994.
17. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the pi6 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27–32, 1994.
18. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436–440, 1994.
19. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S., and Nakamura, Y. Frequent somatic mutation of the MTS1/CDK41 (Multiple tumor suppressor/cycl in-de pendent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54: 3396–3397, 1994.
20. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753–756, 1994.
21. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H. J., Tucker, M. A., and Dracopoli, N. C. Germline pl6 mutations in familial melanoma. Nat. Genet., 8: 15–21, 1994.
22. Kamb, A., Shattuck-Eidens, S., Eeles, R., et al. Analysis of CDKN2 (MTS1) as a candidate for the chromosome 9p melanoma susceptibility locus (MLM). Nat. Genet., 8: 22–26, 1994.
23. Weaver-Feldhaus, J., Gruis, N. A., Neuhausen, S., Le Paslier, D., Stockert, E., Skolnick, M. H., and Kamb, A. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc. Natl. Acad. Sci. USA, 91: 7563–7567, 1994.
24. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
25. Bates, S., Bonetta, L., MacAllan, D., Parry, D., Holder, A., Dickson, C., and Peters, G. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin Dl. Oncogene, 9: 71–79, 1994.
26. Liu, Q., McClure, M., Frye, C., Weaver-Feldhaus, J., Eddington, K., Skolnick, M. H., Fujimura, F. K., and Kamb, A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10: 1061–1067, 1995.
27. Elstad, M. R., Prescott, S. M., McLntyre, T. M., and Zimmerman, G. A. Synthesis and release of platelet-activating factors by stimulated human mononuclear phagocytes. J. Immunol., 140: 1618–1624, 1988.
28. Cannon-Albright, L. A., Goldgar, G., Meyer, L. J., et al. Assignment of a melanoma susceptibility locus, MLM, to chromosome 9pl3-p22. Science (Washington DC), 258: 1148–1152, 1992.
29. INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045–11049, 1994.
30. Kozak, M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 44: 283–292, 1986.
31. Firpo, E. J., Koff, A., Solomon, M. J., and Roberts, J. M. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol., 14: 4889–4901, 1994.
32. Kip1) of cyclin-dependent kinase 4 activation. Cell, 79: 487–496, 1994.
33. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9–22, 1994.
34. Slingerland, J. M., Hengst, L., Pan, C-H., Alexander, D., Stampfer, M. R., and Reed, S. I. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor 0-arrested epithelial cells. Mol. Cell. Biol., 14: 3683–3694, 1994.
35. Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E., and Sidransky, D. Rates of pi6 (MTS1) mutations in primary tumors with 9p loss. Science (Washington DC), 265: 415–416, 1994.
36. Spruck, C. H. I., Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. S., Lin, M-F., Gonzales, F., Tsai, Y. C., and Jones, P. A. pl6 gene in uncultured tumors. Nature (Lond.), 370: 183–184, 1994.
37. Cobrinik, D., Dowdy, S., Hinds, P., Mittnacht, S., and Weinberg, R. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem. Sci., 17: 312–315, 1992.
38. INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood, 84: 4038–4044, 1994.
39. INK4A transcript. Cancer Res., 55: 2995–2997, 1995.
40. Andrews, B. J., and Herskowitz, I. Regulation of cell cycle-dependent gene expression in yeast. J. Biol. Chem., 265: 14057–14060, 1990.
41. 1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol., 10: 581–591, 1991.
42. PSK-J3/cdk4) for mammalian D type Gl cyclins. Cell, 71: 323–334, 1992.
43. Hori, T., Uchiyama, T., Tsudo, M., Umadome, H., Ohno, H., Fukuhara, S., Kita, K., and Uchino, H. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood, 70: 1069–1072, 1987.